Epclusa is a fixed-dose combination therapy consisting of sofosbuvir and velpatasvir, approved by the US FDA for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.
How to Use Epclusa
Standard Dosing Regimen for Adults
The recommended dose for adult patients is one tablet once daily (containing 400 mg sofosbuvir and 100 mg velpatasvir), which can be taken with or without food.
Treatment Cycle Setting
(1) The standard treatment cycle is 12 weeks, depending on the patient's specific condition.
(2) Patients without cirrhosis or with compensated cirrhosis: Epclusa monotherapy.
(3) Patients with decompensated cirrhosis: Requires combination therapy with ribavirin.
Epclusa Dosage Adjustment
Patients with Abnormal Liver and Kidney Function
(1) No dose adjustment is required for patients with renal impairment, including those with end-stage renal disease requiring dialysis. (2) However, close clinical monitoring is necessary in patients with end-stage renal disease.
(3) No dose adjustment of Epclusa is required in patients with varying degrees of liver damage, including Child-Pugh A, B, and C patients, providing convenience for liver disease patients.
Differentiated Dosing for Children Based on Weight
(1) Less than 17 kg: 150 mg sofosbuvir and 37.5 mg velpatasvir daily.
(2) 17-30 kg: 200 mg sofosbuvir and 50 mg velpatasvir daily.
(3) At least 30 kg: 400 mg sofosbuvir and 100 mg velpatasvir daily.
Specific Dosage Form Selection
(1) <17 kg: 150 mg/37.5 mg oral granules.
(2) 17-30 kg: 200 mg/50 mg oral granules or tablets can be used.
(3) Weight ≥30kg: Use 400mg/100mg tablets or two 200mg/50mg oral granules.
Epclusa (Epclusa) Special Population Use:
Liver Transplant Recipients:
For treatment-naïve and previously treated liver transplant recipients, if they do not have cirrhosis or have compensated cirrhosis, the recommended regimen is once-daily Epclusa for 12 weeks.
Oral Granule Usage Guidelines:
(1) Epclusa is specifically available in oral granule form for young children or patients with dysphagia.
(2) Granules can be taken directly or mixed with food.
(3) For children under 6 years of age, it is recommended to take with food to increase tolerability.
(4) Specific instructions: Sprinkle the granules onto one or more spoonfuls of non-acidic soft food (such as pudding, chocolate syrup, or ice cream).
(5) Take within 15 minutes after mixing.
(6) Avoid chewing throughout the process to prevent bitterness from affecting compliance.
For patients co-infected with HCV/HIV, it is recommended to administer medication according to the standard recommended dose and treatment duration.
